Everist Health™ is a personalized medicine company which develops and commercializes medically unique diagnostics, prognostics and therapeutic selection technologies which help physicians improve medical outcomes and reduce the total cost of care.

We are a closely held, privately owned company, headquartered in Ann Arbor, Michigan. The principle shareholders of Everist Health are large family investment offices headquartered in Denver, Colorado; Sioux Falls, South Dakota; New York City and Naples, Florida.

Everist Health was formed two years ago by combining the assets, product portfolios, capabilities and IP of Genetics Squared, Inc. and Angiologix Inc. Everist Health has successfully completed several cash-based company and product acquisitions, all financed by the current family office shareholder base. Everist Health's patent protected products aid physicians in early diagnosis of diseases (such as cancer, cardiovascular disease and metabolic disease), long before there are any detectable symptoms and thereby enabling early and more effective treatment while also reducing healthcare costs and saving lives.

Our lead product is the AngioDefender™ cardiovascular disease (CVD) diagnostic system. It is the world's first non-invasive device that successfully combines patent-protected sensor technology with a sophisticated software algorithm to quickly and cost effectively help physicians assess the presence of early-stage CVD and atherosclerosis.